iSEEde
Bioc currentiSEE extension for panels related to differential expression analysis
Release Lineage
Entered 3.18 · Oct 25, 2023
Current · Requires R 4.6
Description
This package contains diverse functionality to extend the usage of the iSEE package, including additional classes for the panels or modes facilitating the analysis of differential expression results. This package does not perform differential expression. Instead, it provides methods to embed precomputed differential expression results in a SummarizedExperiment object, in a manner that is compatible with interactive visualisation in iSEE applications.
Test coverage
Line coverage
–
Expression
–
Tests / Examples
–
Functions
12 9 exported
Complexity
1.5 avg / 4 max
Call network
12 nodes / 0 edges
Test coverage is not measured for Bioconductor packages; nodes fall back to a neutral fill.
Call graph
Open call graph →Lowest coverage
Per-function coverage is not measured for this package yet.
Code
Structure
Lines of code
3,733
Files
60
Compiled share
0%
Has compiled src
No
Language breakdown
API
Exported functions
11
Internal functions
3
Testing & CI
Has tests
Yes
Test-to-code ratio
0.40
testthat edition
3
CI present
Yes
CI type
["github-actions"]
PR gated
Yes
Docs
Roxygen coverage
100%
Health & Security signals
Informational signals; not verdicts.
on.exit coverage
–
Unsafe pattern score
0
Dep constraint coverage
0%
Secret pattern count
0
Bundled 3rd-party code
2 items
Portability & License
Min R version
–
System requirements
–
C++ standard
–
License
Artistic-2.0
License flags
SPDX valid, OSI approved
History
Versions
6
First release
2023-10-24
Latest release
2026-04-28
Avg cadence
182 days
Cold removal rate
–
Dep drift
0
LOC over versions
Per-file churn detail lives in the source pipeline: https://github.com/r-observatory/bioc-code-metrics.
Documentation
- Examples that run
- 100%
- Documented parameters
- 100%
- Return-value docs
- 22%
- References docs
- 0%
Topics
Depended on by (1)
Bioconductor (1)
People
- Kevin Rue-Albrecht author maintainer
- Denali Therapeutics fnd
- Thomas Sandmann contributor